PT  - JOURNAL ARTICLE
AU  - Piccirella, Simona
AU  - Van Neste, Leander
AU  - Fowler, Christopher
AU  - Masters, Colin L
AU  - Fripp, Jurgen
AU  - Doecke, James D.
AU  - Xiong, Chengjie
AU  - Uberti, Daniela
AU  - Kinnon, Paul
TI  - A conformational variant of p53 (U-p53<sup>AZ</sup>) as blood-based biomarker for the prediction of the onset of symptomatic Alzheimer’s disease
AID  - 10.1101/2021.08.23.21261848
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.08.23.21261848
4099  - http://medrxiv.org/content/early/2021/08/25/2021.08.23.21261848.short
4100  - http://medrxiv.org/content/early/2021/08/25/2021.08.23.21261848.full
AB  - Background Ongoing research seeks to identify blood-based biomarkers able to predict the onset and progression of Alzheimer’s disease (AD). A potential biomarker is the unfolded conformational variant of p53, previously observed in individuals in the prodromal and clinical AD stages. In this retrospective study, we compare diagnostic and prognostic performances of measures of the amyloid β load with those of a conformational variant of U-p53 in plasma samples from individuals participating in the Australian Imaging, Biomarkers and Lifestyle (AIBL) cohort.Methods Immunoprecipitation (IP) followed by liquid chromatography (LC) tandem mass spectrometry (MS/MS) and protein sequencing in plasma samples from the AIBL study identified the clinically relevant AZ 284® peptide, representing a measure of the U-p53 conformational variant (U-p53AZ). Based on U-p53AZ quantification via IP/LC electrospray ionisation-coupled MS/MS (AlzoSure® Predict test) on 515 samples from 482 individuals from the AIBL cohort, the predictive performance of U-p53AZ was assessed and compared with amyloid load as measured by amyloid β-positron emission tomography (Aβ-PET). Its predictive performance was determined at 36, 54, 72 and 90 months following baseline assessment.Results U-p53AZ was able to identify individuals with AD dementia with an area under the receiver operating characteristic curve (AUC) of 99%. U-p53AZ outperformed the conventional Aβ-PET measures in predicting the onset of AD dementia both from preclinical (AUC=98%) and prodromal stages (AUC=89%), even 90 months prior to onset (AUC=99%). Additionally, the estimated predictive performance of U-p53AZ was superior (AUC ≥98%) to other risk factors (i.e., gender, Aβ-PET and APOE ε4 allele status) in identifying individuals at high risk for progression to AD.Conclusion These findings support use of U-p53AZ as blood-based biomarker predicting if individuals, at both asymptomatic and MCI stages, would progress to AD at least six years prior to the onset of clinical AD dementia.Competing Interest StatementThe ownership of the 2D3A8 antibody patent rights belongs to Diadem srl, Brescia, Italy. The registered trademark AlzoSure Predict was developed by Diadem srl, Brescia, Italy. SP and PK are employees of Diadem srl, Brescia, Italy. DU is co-founder and CSO of Diadem srl, Spin Off of Brescia University, Brescia, Italy. LVN and CX are consultants of Diadem srl.Funding StatementThis study was funded by Diadem srl, Brescia, Italy.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Human Research Ethics Committee, Research Governance Unit, St Vincent's Healthcare, Australia (no. 028/06)All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData available on request from the authors.AβAmyloid betaAIBLAustralian Imaging, Biomarkers, and LifestyleAUCArea under the receiver operating characteristic curveADAlzheimer’s diseaseAPOE ε4Apolipoprotein E ε4 alleleBACE1β-site amyloid precursor protein-cleaving enzyme 1CIConfidence intervalCNCognitively normalCSFCerebrospinal fluidELISAEnzyme linked immunosorbent assayESIElectrospray ionisationHCDHigher energy collision-induced dissociationHPLCHigh performance liquid chromatographyIPImmunoprecipitationMCIMild cognitive impairmentMRIMagnetic resonance imagingMS/MSTandem mass spectrometryODOther types of dementiasPiB-PETPositron emission tomography utilising Pittsburgh compound BROCReceiver operating characteristicPTMsPost-translational modificationsRNS/ROSReactive nitrogen/reactive oxygen speciesSACISurface-activated chemical ionisationU-p53unfolded p53